Oncologists say drug bill bad for cancer doctors

Article Overview

This article examines a Medicare payment reform measure affecting drugs administered in physician offices, with particular attention to oncology. It summarizes reactions from medical specialty groups, discusses broader implications for practice expense payments and patient access, and notes that other specialties that administer infusion services may also be affected. The piece is relevant to oncologists, gastroenterologists, practice managers, and coding or reimbursement professionals following federal reimbursement policy.